The first US congressional committee hearing on the Trump Administration’s blueprint for lowering drug prices suggests that legislation is possible on a modest suite of reforms but that the most impactful changes may come from administrative action.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?